Navigation Links
Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate)

Results show risk of heart attack comparable to two widely used diabetes medicines

LONDON, June 6, 2007- A study of more than 33,000 type 2 diabetes patients in a real-world setting was published today. This study shows that the incidence of hospitaliations for heart attack, and/or for a surgery known as coronary revascularization for patients on Avandia is the same as for other diabetes treatments. The study results were released in a paper titled “Coronary Heart Disease Outcomes in Patients Receiving Antidiabetic Agents” in Pharmacoepidemiology and Drug Safety.

These data, also described in a letter published online last week (May 30, 2007) in the medical journal The Lancet, are further evidence that the ischemic cardiovascular safety of Avandia is comparable to the most commonly used type 2 diabetes treatments – as evidenced in long-term prospective trials, such as ADOPT and DREAM. The findings conflict with a hypothesis generated by the recently published meta-analysis in the New England Journal of Medicine that raised concerns regarding ischemic risks with Avandia.

Based on an observational cohort study from a large U.S.managed-care database, this research was commissioned by GlaxoSmithKline as part of its commitment to the ongoing monitoring and assessment of the safety of Avandia. The study was designed to compare the risk of heart attack and coronary revascularization in type 2 diabetes patients taking Avandia, metformin or sulfonylurea – either alone, as two medicines combined and in combination with insulin. The study populations were matched to ensure that the cohort groups were similar in terms of their baseline risk factors for cardiovascular disease. Patients were followed for an avera ge of slightly over a year.

The results demonstrate that:

• there was no difference in the overall incidence of heart attack and coronary revascularization with Avandia-containing therapies (1.75 events per 100 person-years) versus non-Avandia containing therapies (1.76 events per 100 person-years) (hazard ratio 0.93, 95% CI 0.80 – 1.10);

• there was no difference in the risk of either heart attack (hazard ratio 0.92, 95% CI 0.73 – 1.16) or coronary revascularization (hazard ratio 0.94, 95% CI 0.79 – 1.12) - with Avandia-containing therapies compared to non-Avandia containing therapies;

• there was no difference in the risk of the composite outcome with Avandia monotherapy compared to metformin monotherapy (hazard ratio 1.07, 95% CI: 0.85 – 1.34), and similarly with Avandia monotherapy compared to sulfonylurea monotherapy (hazard ratio 0.82, 95% CI: 0.67 – 1.02);

• there was no difference in the risk of composite outcome with Avandia in combination with insulin therapy compared to other oral antidiabetic agents in combination with insulin (hazard ratio 0.88, 95% CI: 0.59 – 1.32).

Avandia is an effective medicine that is an important treatment for millions of patients who are using it to manage their diabetes, a disease with potentially devastating consequences if left unmanaged.

Glossary of Terms:

Coronary revascularization - the process of restoring blood flow of oxygen to the heart via a surgical procedure to bypass blockages or obstructions in the coronary arteries

Cohort - a group within a given population followed over a period of time

CI (con fidence interval) - quantifies the range that covers the mean via an upper and lower limit for the actual value

Patient year - the cumulative amount of time that a patient has taken a particular medicine as measured in years.

Enquiries:

UK Media enquiries:

Philip Thomson

(020) 8047 5502

Joss Mathieson

(020) 8047 5502

Gwenan White

(020) 8047 5502

US Media enquiries:

Nancy Pekarek

(215) 751 7709

Alice Hunt

(215) 751 7709

Mary Anne Rhyne

(919) 483 2839

European Analyst/Investor enquiries:

Anita Kidgell

(020) 8047 5542

David Mawdsley

(020) 8047 5564

Sally Ferguson

(020) 8047 5543

US Analyst/ Investor enquiries:

Frank Murdolo

(215) 751 7002

Tom Curry

(215) 751 5419


'"/>




Related medicine technology :

1. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
2. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
3. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
4. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
5. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
6. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
7. MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
8. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
9. Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016 Summary Breast cancer, a ... the most common cancer in women worldwide, accounting for ... prevalent. The number of women diagnosed with breast cancer ... number of deaths has declined due to earlier diagnosis ... been revolutionized in the past four decades, especially with ...
(Date:2/4/2016)... Ohio, Feb. 4, 2016 Mettler-Toledo International Inc. ... for 2015.  Provided below are the highlights: ... quarter compared with the prior year.  Reported sales decreased ... the quarter. , Net earnings per diluted share ... the prior- year period.  Adjusted EPS was $4.65, an ...
(Date:2/4/2016)... , Feb. 4, 2016  Blueprint Medicines Corporation ... and developing highly selective investigational kinase medicines for ... appointment to its board of directors of ... nearly 30 years of industry-related experience. ... Blueprint Medicines. "Lonnel,s strong strategic experience developing and ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... The ... Popeyes Louisiana Kitchen restaurants, launched the 14th annual “Appetite for a Cure” campaign ... with muscular dystrophy, ALS and related diseases that severely limit strength and mobility. ...
(Date:2/5/2016)... York (PRWEB) , ... February 05, 2016 , ... Looking ... answer may be at the tips of your toes. Foot massage, whether administered by ... as pure comfort and relaxation. The American Board of Multiple Specialties in Podiatry ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an active ... Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division ... completed his first three-year term as chief and began a second three-year term in ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... US ... Yoga Studio in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio ... seacoast, just one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses ...
(Date:2/5/2016)... ... ... The American public tends to feel uncomfortable about drinking recycled waste water ... well water. The recent experience with lead contaminated water in Flint, Michigan, according to ... increasing public acceptance of recycled waste water as drinking water. , The Flint ...
Breaking Medicine News(10 mins):